First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial
EuroIntervention 2018;13:2026-2035 published online September 2017. DOI: 10.4244/EIJ-D-17-00462
Clemens von Birgelen1, MD, PhD; Taku Asano2,3, MD; Giovanni Amoroso4, MD, PhD; Adel Aminian5, MD; Salvatore Brugaletta6, MD, PhD; Mathias Vrolix7, MD; Rosana Hernandez-Antolín8, MD, PhD; Pim van de Harst9,10, MD, PhD; Andres Iñiguez11, MD, PhD; Luc Janssens12, MD; Pieter C. Smits13, MD, PhD; Joanna J. Wykrzykowska2, MD, PhD; Vasco Gama Ribeiro14, MD; Hélder Pereira15, MD; Pedro Canas da Silva16, MD; Jan J. Piek2, MD, PhD; Yoshinobu Onuma17,18, MD, PhD; Patrick W. Serruys1. Thoraxcentrum Twente, Enschede, the Netherlands; 2. Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 3. St. Luke’s International Hospital, Tokyo, Japan; 4. Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; 5. Centre H
Aims: A second iteration of a sirolimus-eluting stent (SES) that has a biodegradable PLGA polymer coating with an electrografting base layer on a thin-strut (80 µm) cobalt-chromium platfo
